BioSpace News Archive

Policy

Verona Secures Up To $650M in Funding as it Gears Up for Potential COPD Approval and Launch

Anticipating approval for its COPD therapy ensifentrine, Verona has entered into a $650 million financing deal with Oaktree Capital Management and OMERS Life Sciences.

May 10, 2024
·
2 min read
·
Tristan Manalac
Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine

Sanofi will hand Novavax $500 million upfront for its COVID-19 vaccine, which it will co-commercialize and develop into a combination flu-COVID vaccine.

May 10, 2024
·
1 min read
·
Kate Goodwin
Business

Bluebird Boasts Nearly 140% Revenue Jump, Still Misses Target

With 15 patients started across its three gene therapies, bluebird bio claims a 138% year-over-year revenue growth and aims to initiate up to around 100 new patients in the current year.

May 10, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Cell and Gene Therapies Still Have Long Way to Go in Fulfilling Promise

While these technologies are now a therapeutic reality, the ASGCT 2024 annual meeting this week was a reminder of just how far we are from widespread use.

May 10, 2024
·
4 min read
·
Greg Slabodkin
ASGCT24: Translational Research Powering Potentially Transformative Therapies

Friday’s agenda highlighted some of the pivotal translational studies, as well as the researchers who are making breakthroughs in genetic therapies.

May 10, 2024
·
2 min read
·
Greg Slabodkin
Business

Royalty Pharma Drops $525M for Royalties and Milestones on Sanofi-Licensed MS Therapy

With its $525 million investment, Royalty Pharma will acquire the royalties and milestones for ImmuNext’s anti-CD40 therapy frexalimab, which is currently in Phase III trials for multiple sclerosis.

May 10, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Five Deaths in Prostate Cancer Trial Send MacroGenics’ Stock Plummeting

Two of the five fatalities were found to be unrelated to MacroGenics’ investigational antibody-drug conjugate vobra duo, while the other three are still under investigation.

May 10, 2024
·
2 min read
·
Tristan Manalac
Policy

SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer

SN Bioscience Co. Ltd. announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer for SNB-101, a new drug for polymer nanoparticle anticancer under clinical trial.

May 10, 2024
·
3 min read
BioCapital

Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has entered into a co-exclusive licensing agreement with Sanofi.

May 10, 2024
·
8 min read
Business

Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced its financial results and operational highlights for the first quarter ended March 31, 2024.

May 10, 2024
·
16 min read